Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

被引：2
|
作者：
Jindy, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Nguyen, Charles B.
Nizam, Amanda
Basu, Arnab
Bilen, Mehmet Asim
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Emamekhoo, Hamid
Hoimes, Christopher J.
Khaki, Ali Raza
Gupta, Shilpa
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[5] Cleveland Clin, Cleveland, OH USA
[6] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA
[12] Univ Wisconsin, Madison, WI USA
[13] Duke Univ, Duke Canc Inst, Durham, NC USA
[14] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA USA
[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[16] Univ Washington, Div Hematol & Oncol, Seattle, WA USA
[17] Fred Hutchinson Canc Ctr, Seattle, WA USA
[18] Dana Farber Canc Inst, Boston, MA USA
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA
[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-12099; 261-492-3532-2370-7650-2700; 261-566-9263; 4; 2; 3224; 3; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [11] Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
    Nizam, A.
    Zhang, L.
    Jindal, T.
    Nguyen, C. B.
    Alhalabi, O.
    Basu, A.
    Evans, S. P.
    Hoimes, C. J.
    Zakharia, Y.
    Milowsky, M. I.
    Kilari, D.
    Shah, S. A.
    Davis, N. B.
    Emamekhoo, H.
    Gupta, S.
    Bellmunt, J.
    Grivas, P.
    Campbell, M. T.
    Alva, A.
    Koshkin, V. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1219 - S1219
  • [12] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Takahashi, Shunji
    Uemura, Motohide
    Kimura, Tomokazu
    Kawasaki, Yoshihide
    Takamoto, Atsushi
    Yamaguchi, Akito
    Melhem-Bertrandt, Amal
    Gartner, Elaina M.
    Inoue, Takashi
    Akazawa, Rio
    Kadokura, Takeshi
    Tanikawa, Toshiki
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1056 - 1066
  • [13] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
    Shunji Takahashi
    Motohide Uemura
    Tomokazu Kimura
    Yoshihide Kawasaki
    Atsushi Takamoto
    Akito Yamaguchi
    Amal Melhem-Bertrandt
    Elaina M. Gartner
    Takashi Inoue
    Rio Akazawa
    Takeshi Kadokura
    Toshiki Tanikawa
    Investigational New Drugs, 2020, 38 : 1056 - 1066
  • [14] Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    ANTICANCER RESEARCH, 2024, 44 (07) : 3025 - 3032
  • [15] Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
    Mantia, Charlene M.
    Sonpavde, Guru
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) : 449 - 455
  • [16] Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2022, 207 (01): : 228 - 228
  • [17] Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    Kuroiwa, Kentaro
    Seki, Narihito
    Fujimoto, Naohiro
    Nakamura, Motonobu
    ANTICANCER RESEARCH, 2024, 44 (08) : 3409 - 3417
  • [18] Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer
    Petrylak, Daniel P.
    Chia, Yen Lin
    Yu, Evan Y.
    Powles, Thomas
    Flaig, Thomas W.
    Loriot, Yohann
    O'Donnell, Peter H.
    Heath, Elisabeth I.
    Kojima, Takahiro
    Park, Se Hoon
    Sonpavde, Guru P.
    Picus, Joel
    Matsubara, Nobuaki
    Obara, Wataru
    Chudasama, Vaishali
    Poondru, Srinivasu
    Harrison, Michael
    Kim, Eric
    Brancato, Sam Joseph
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [19] Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
    Minato, Akinori
    Furubayashi, Nobuki
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Song, Yoohyun
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Kuroiwa, Kentaro
    Seki, Narihito
    Tomisaki, Ikko
    Nakamura, Motonobu
    Harada, Kenichi
    Fujimoto, Naohiro
    ANTICANCER RESEARCH, 2024, 44 (08) : 3419 - 3426
  • [20] A CASE OF ENFORTUMAB VEDOTIN TOXICITY IN A PATIENT WITH ADVANCED UROTHELIAL CELL CARCINOMA
    Grigsby, Charles
    Thebert, Alexander
    Pijut, Kyle
    Woodward, Blake
    Bastin, Melissa Thompson
    Soper, Melissa
    Fozzard, Andrew
    CRITICAL CARE MEDICINE, 2024, 52
12345